Floatz logo

Di-Leu16-Il2

Splenic Marginal Zone Lymphoma

City of Hope Medical Centerprotein_peptidePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Splenic Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BB
Zanubrutinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Di-Leu16-Il2 is also rated in:

anaplastic large cell lymphomaDormant
C
Indicative ·
38 / 100
View asset →
primary cutaneous B-cell lymphomaDormant
C
Indicative ·
38 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →